form8k.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (date of earliest event reported): March 4, 2008
CENTRAL
EUROPEAN MEDIA ENTERPRISES LTD.
(Exact
name of registrant as specified in its charter)
BERMUDA
|
|
0-24796
|
|
98-0438382
|
(State
or other jurisdiction of incorporation and organisation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
|
|
|
|
Clarendon
House, Church Street, Hamilton
|
|
|
|
HM
11 Bermuda
|
(Address
of principal executive offices)
|
|
|
|
(Zip
Code)
|
Registrant's
telephone number, including area code: (441) 296-1431
Not
applicable
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
1.01 Entry into a Material Definitive Agreement
On March
10, 2008, Central European Media Enterprises Ltd. (the “Company” or “CME”) issued $475
million in aggregate principal amount of 3.50% Convertible Senior Notes due 2013
(the “Notes”). The
Notes were initially sold pursuant to a Purchase Agreement dated March 4, 2008
among the Company, Lehman Brothers Inc., J.P. Morgan Securities Inc., Deutsche
Bank Securities Inc., BNP Paribas and ING Bank N.V., London Branch. The terms of
the Notes are governed by an Indenture dated as of March 10, 2008 among the
Company, Central European Media Enterprises N.V. (“CME NV”), CME Media
Enterprises B.V. (“CME
BV”) and The Bank of New York, as trustee and security trustee (the
“Indenture”).
The Notes were sold to the initial purchasers at a purchase price equal to
98.00% of the principal amount plus accrued interest, if any. The Notes, offered
to qualified institutional buyers pursuant to Rule 144A under the U.S.
Securities Act of 1933, as amended (the “Securities Act”), are
senior obligations of CME and rank equally in right of payment with its existing
and future senior debt.
The Notes
bear interest at 3.50% per year and will mature on March 15, 2013. Prior to
December 15, 2012, the Notes will be convertible following certain events as
specified in the Indenture and from that date, at any time, based on an initial
conversion rate of 9.5238 shares of CME's Class A common stock per $1,000
principal amount of Notes (which is equivalent to an initial conversion price of
approximately $105.00 or a 25% conversion premium based on the closing sale
price of $84.00 per share of CME's Class A common stock on March 4, 2008). The
conversion rate is subject to adjustment if CME makes certain distributions to
the holders of its Class A common stock, undergoes certain corporate
transactions or a fundamental change, and in other circumstances specified in
the Notes. From time to time up to and including December 15,
2012, CME will have the right to elect to deliver (i) shares of CME's
Class A common stock or (ii) cash and, if applicable, shares of CME's Class A
common stock upon conversion of the Notes. At present, CME has elected to
deliver cash and, if applicable, shares of Class A common stock. In
addition, the holders of the Notes will have the right to put the Notes to CME
following the occurrence of fundamental changes, as specified in the Indenture
(including a change of control, certain mergers, insolvency and a
delisting).
The Notes are jointly and
severally guaranteed, subject to certain limits imposed by local law, on a
senior unsecured basis initially by CME NV and CME BV (collectively, the
“Subsidiary
Guarantors”),
two wholly-owned subsidiaries of CME. The Notes are secured by
a security interest in the shares of the Subsidiary Guarantors pursuant to a
Deed of Pledge with respect to the shares of CME BV and a Pledge Agreement with
respect to the shares of CME NV, each dated March 10, 2008, and certain
contractual rights of CME pursuant to a Security Assignment between the Company,
CME BV and The Bank of New York, dated March 10, 2008. This collateral is
currently pledged to secure CME’s obligations under (i) its €245.0 million
aggregate principal amount of 8.25% Senior Notes due 2012 (the “2005 Notes”) and (ii)
its €150.0
million aggregate principal amount of Senior Floating Rate Notes due 2014 (the
“2007 Notes”),
and (iii) its €50.0 million and €100.0 million revolving loan agreements with
the European Bank for Reconstruction and Development (“EBRD”). Under
applicable law, these security interests will rank prior to the security
interest in favor of the holders of the Notes. However, the creditors have
agreed, among other things, to share any proceeds received by any party thereto
upon enforcement of any of the security on a ratable basis pursuant to an
intercreditor agreement dated March 10, 2008 (the “Intercreditor
Agreement”) among CME, the Subsidiary Guarantors, BNY Corporate Trustee
Services Limited and The Bank of New York, as trustee and security trustee,
respectively, for the 2007 Notes, The Bank of New York (formerly JPMorgan Chase
Bank, N.A., London Branch), as trustee and security trustee for the 2005 Notes
and EBRD. The security granted in favor of the holders of the Notes may be
released in certain circumstances.
In
connection with the issuance of the Notes, CME entered into capped call
transactions with respect to its shares of Class A common stock on March 4, 2008
(collectively the “Option
Agreements”). The Option Agreements are with each of BNP
Paribas, Deutsche Bank AG, London Branch and
Deutsche Bank Securities Inc. (as agent), and Lehman Brothers OTC Derivatives
Inc. and Lehman Brothers, Inc. (as agent), each of which is an initial purchaser
of the Notes or an affiliate of an initial purchaser of the Notes. The capped
call transactions are not part of the terms of the Notes and do not affect the
rights of the holders of the Notes under the Indenture.
Pursuant
to the Option Agreements, CME has purchased call options for consideration of
approximately $63.3 million that are exercisable, for no additional
consideration, in the event of a conversion of the Notes or at the maturity date
of the Notes (March 15, 2013). The value CME will receive (in
cash or shares of its Class A common stock) upon the exercise of an option is
based on the number of shares of its Class A common stock affected by such
transaction multiplied by the difference between the conversion price of the
Notes ($105.00, as may be adjusted from time to time) and the trading price at
such time, up to the point the trading price reaches a cap ($151.20, as adjusted
from time to time). The terms of these options are subject to
adjustment in certain circumstances, including changes to the conversion rate of
the Notes, or cancellation and early payment. Assuming no adjustment
to the terms of the options, it is expected that the exercise of the options
will reduce or, in certain circumstances, substantially eliminate potential
dilution of CME’s shares of Class A common stock in the event that the trading
price per share of its Class A common stock at the time of exercise exceeds the
conversion price specified above.
In connection with the
issuance and sale of the Notes, the Company also entered into a Registration
Rights Agreement with Lehman Brothers Inc., J.P. Morgan Securities Inc.,
Deutsche Bank Securities Inc., BNP Paribas and ING Bank N.V., London Branch,
dated March 10, 2008 (the “Registration
Rights Agreement”). Pursuant to the
Registration Rights Agreement, CME has agreed to (i) file with the SEC
not later than 120 days after the date of original issuance of the Notes, a
shelf registration statement covering resales by holders of the shares of its
Class A common stock issuable upon conversion of the Notes (provided that this
will be an automatic shelf registration statement if CME is eligible to use an
automatic shelf registration statement at the time of filing); (ii) use
reasonable best efforts (if CME is not eligible to use an automatic shelf
registration statement at the time of filing) to cause such registration
statement to become effective as promptly as is practicable, but in no event
later than 180 days after the date of original issuance of the Notes; and (iii)
use reasonable best efforts to keep the registration statement continuously
effective until the earlier of: (A) the date when the holders of transfer
restricted shares of CME’s Class A common stock issuable upon conversion of the
Notes that are not affiliates of CME are able to sell all such securities
immediately without restriction under Rule 144 under the Securities Act; or (B)
the date when all transfer restricted shares of CME's Class A common stock
issuable upon conversion of the Notes are registered under the
shelf registration statement and sold pursuant thereto or have ceased
to be outstanding (whether as a result of repurchase and cancellation or
otherwise).
CME
intends to use net proceeds from the offering, after taking into account the
cost of the Option Agreements, to purchase additional ownership interests in
CME's operations in Ukraine (as reported in the Company’s Annual Report on Form
10-K for the year ended December 31, 2007) and for general corporate
purposes.
Item 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance
Sheet Arrangement of a Registrant.
The
response to Item 1.01 is hereby incorporated into this
Item 2.03.
Item 3.02
Unregistered Sales of Equity Securities.
The
response to Item 1.01 is hereby incorporated into this Item 3.02. The
Notes referred to in the response to Item 1.01 are convertible into shares
of Class A common stock of CME, as described in such response.
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, we have duly caused
this report to be signed on our behalf by the undersigned thereunto duly
authorized.
Date:
March 10, 2008
|
/s/ Wallace
Macmillan
|
|
Wallace
Macmillan
|
|
Chief
Financial Officer
|